<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian journal of Pediatric Hematology and Oncology</title>
<title_fa>Iranian journal of Pediatric Hematology and Oncology</title_fa>
<short_title>Iran J Ped Hematol Oncol</short_title>
<subject>Medical Sciences</subject>
<web_url>http://ijpho.ssu.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>2008-8892</journal_id_issn>
<journal_id_issn_online>2228-6993</journal_id_issn_online>
<journal_id_pii>8</journal_id_pii>
<journal_id_doi>7</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>14</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>13</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1400</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2022</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>12</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>fa</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Evaluating the blood toxicity of functionalized graphene-arginine with anticancer drug ginsenoside Rh2 in balb/c mouse model with breast cancer</title>
	<subject_fa>قلب</subject_fa>
	<subject>Heart</subject>
	<content_type_fa>پژوهشي</content_type_fa>
	<content_type>Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div&gt;&lt;strong&gt;Background: &lt;/strong&gt;Gensenoside Rh2 is an anticancer drug with low toxicity and stability in the body. The aim of this study was to evaluate the blood toxicity of functionalized graphene-arginine with anticancer drug ginsenoside Rh2 in balb/c mouse model with breast cancer.&lt;br&gt;
&lt;strong&gt;Materials and Methods: &lt;/strong&gt;Graphene-Arginine (G-Arg) and Graphene-Arginine-ginsenoside Rh2 (G-Arg-Rh2) were synthesized using microwave method. For evaluation of blood toxicity, 32 mice with breast tumors were randomly divided into 4 groups: control (3mg/kg 6 mg/kg PBS sterile), group 1 (6 mg / kg ginsenoside), group 2 (3 mg / kg G-Arg), and group 3 (3 mg/kg G-Arg-Rh2). Treatment was done intravenously once every three days for 32 days. Finally, blood factors were also examined by sampling from the heart.&lt;br&gt;
&lt;strong&gt;Results: &lt;/strong&gt;Complete functionalization was proven by FTIR and Raman. Examination of blood factors showed that white blood cells had a very small increase. Anova test showed significant difference among four groups in term of WBC count (p=0.016). Pair sample T test showed that there was significant difference between control and group 1(p=0.036) and control and group 2 (p=0.036). There was no significant difference between control and group 3 (p=0.051). Other blood factors had no significant difference among examined groups (p&gt;0.05).&lt;br&gt;
&lt;strong&gt;Conclusion: &lt;/strong&gt;Based on results, after treatment with all designed nanostructures, only white blood cells had a very small increase and inflammatory reactions were statistically similar in all groups. This indicates the high efficiency of designed drug.&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Gensenoside Rh2, balb/c mouse, Graphene-Arginine, Graphene-Arginine-ginsenoside Rh2, blood</keyword>
	<start_page>10</start_page>
	<end_page>16</end_page>
	<web_url>http://ijpho.ssu.ac.ir/browse.php?a_code=A-10-869-2&amp;slc_lang=fa&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Shervin Dokht </first_name>
	<middle_name></middle_name>
	<last_name>Farhangfar</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Biology, Science and Arts University, Yazd, Iran</affiliation>
	<affiliation_fa>Department of Biology, Science and Arts University, Yazd, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Farzaneh </first_name>
	<middle_name></middle_name>
	<last_name>Fesahat</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid>0000-0002-3743-4449</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</affiliation>
	<affiliation_fa>Reproductive Immunology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Sayed Mohsen </first_name>
	<middle_name></middle_name>
	<last_name>Miresmaeili</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Biology, Science and Arts University, Yazd, Iran</affiliation>
	<affiliation_fa>Department of Biology, Science and Arts University, Yazd, Iran</affiliation_fa>
	 </author>


	<author>
	<first_name>Hadi</first_name>
	<middle_name></middle_name>
	<last_name>Zare-Zardini</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>hadizarezardini@gmail.com</email>
	<code></code>
	<orcid>0000-0002-1501-2560</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</affiliation>
	<affiliation_fa>Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran</affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
